Several days after Valeant Pharmaceuticals International executives pledged to establish a committee to review its drug pricing practices, the Senate Aging Committee released a treasure trove of documents related to the company’s internal pricing strategies.
The 818-page file includes emails between company executives as well as internal marketing plans for the company’s drugs.
Included in the document dump are the questions Congress posed to Valeant about its pricing history of Nitropress, Isuprel, Syprine and Cuprimine. The documents include company responses to those questions and charts that show sales prices compared to profits from 2013 to 2015. Other documents include market strategies and launch plans for the drugs in question.